# CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL

> **NCT05659628** · PHASE1 · RECRUITING · sponsor: **Ningbo No. 1 Hospital** · enrollment: 24 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **COMBINATION_PRODUCT:** CD19-7×19 CAR-T combined with Tislelizumab

## Key facts

- **NCT ID:** NCT05659628
- **Lead sponsor:** Ningbo No. 1 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12
- **Primary completion:** 2024-12
- **Final completion:** 2026-12
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2022-12-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05659628

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05659628, "CD19 CAR-T Expressing IL-7 and CCL19 Combined With Anti-PD1 in RR-DLBCL". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05659628. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*